Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Griffiths, Robert ^a,b   Gleeson, Michelle ^a   Knopf, Kevin ^c   Danese, Mark ^a  

^a Outcomes Insights Inc   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGE DISTRIBUTION; AGED; AGING; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; EFFECT SIZE; ETHNICITY; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OVERALL SURVIVAL; RACE DIFFERENCE; SOCIOECONOMICS; THROMBOCYTOPENIA; ETHNOLOGY; HEALTH CARE DISPARITY; HEALTH DISPARITY; MEDICARE; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; ONCOLOGY; REGISTER; UNITED STATES;

AGED; AGED, 80 AND OVER; FEMALE; HEALTH STATUS DISPARITIES; HEALTHCARE DISPARITIES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MEDICAL ONCOLOGY; MEDICARE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGISTRIES; SEER PROGRAM; UNITED STATES;

EID: 78149322657     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-625     Document Type: Article

References (31)

1. American Cancer Society, Cancer Facts & Figures 2010. 2010, Atlanta: American Cancer Society.
2. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998, 16:2780-95.
3. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology™ Non-Hodgkin's Lymphomas V.1.2010. National Comprehensive Cancer Network.
4. Coiffer B. Standard treatment of advanced-stage diffuse large-B cell lymphoma. Semin Hematol 2006, 43:213-20. 10.1053/j.seminhematol.2006.07.004, 17027655.
5. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan T, Mize EM, Glick JH, Coltman CA, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993, 328:1002-6. 10.1056/NEJM199304083281404, 7680764.
6. Coiffer B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-42. 10.1056/NEJMoa011795, 11807147.
7. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005, 23(22):5027-33. 10.1200/JCO.2005.09.137, 15955905.
8. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, . MabThera International Trial Group CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7:379-91. 10.1016/S1470-2045(06)70664-7, 16648042, MabThera International Trial Group.
9. Habermann T, Weller E, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006, 24(19):3121-27. 10.1200/JCO.2005.05.1003, 16754935.
10. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005, 23(18):4117-26. 10.1200/JCO.2005.09.131, 15867204.
11. Smedly BD, Stith AY, Nelson AR, . Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care Unequal treatment: Confronting racial and ethnic disparities in health care. 2003, The National Academies Press. Washington, DC, Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care.
12. Curtis E, Quale C, Haggstrom D, Smith-Bindman R. Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics?. Cancer 2008, 112:171-80. 10.1002/cncr.23131, 2674622, 18040998.
13. Gomez SL, O'Malley CD, Stroup A, Shema SJ, Satariano WA. Longitudinal, population-based study of racial/ethnic differences in colorectal cancer survival: impact of neighborhood socioeconomic status, treatment and comorbidity. BMC Cancer 2007, 7:193. 10.1186/1471-2407-7-193, 2228311, 17939875.
14. Wang M, Burau KD, Fang S, Wang H, Du XL. Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma. Cancer 2008, 113:3231-41. 10.1002/cncr.23914, 18937267.
15. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002, 40:IV-18.
16. National Cancer Institute Overview of the SEER Program [Internet]. 2010, Bethesda: National Cancer Institute, [Accessed 8/27/10], National Cancer Institute., http://seer.cancer.gov/about/
17. National Cancer Institute Overview of the SEER Program [Internet]. 2010, Bethesda: National Cancer Institute, [Accessed 8/27/10], National Cancer Institute., http://healthservices.cancer.gov/seermedicare/overview/linked.html
18. North American Association of Central Cancer Registries: NAACCR ICD-O-3 Implementation Work Group. Guidelines for ICD-O-3 Implementation. [Accessed 6/10/10]., http://www.naaccr.org
19. World Health Organization International Classification of Diseases for Oncology. 2000, World Health Organization, 3, World Health Organization.
20. Practice Management Information Corporation. ICD-9-CM. 2005, Los Angeles: Practice Management Information Corporation, 6.
21. Practice Management Information Corporation. HCPCS. 2005, Los Angeles: Practice Management Information Corporation.
22. ResDAC Research Data Assistance Center. CMS 301: Using SEER/Medicare Data for Research. 2008, ResDAC Minneapolis, MN, ResDAC.
23. Fritz A, Ries L, . eds SEER Program Code Manual. 1998, Bethesda: Cancer Statistics Branch, Surveillance Program, Div of Cancer Control and Pop Sciences, National Cancer Institute, National Institutes of Health, Public Health Service, U.S. Dept of Health and Human Services, 3, eds.
24. Young JL, Roffers SD, Ries LAG, Fritz AG. SEER Summary Staging Manual - 2000: Codes and Coding Instructions 2001 National Cancer Institute. NIH Pub. No. 01-4969. 2001,
25. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000, 53:1258-67. 10.1016/S0895-4356(00)00256-0, 11146273.
26. National Cancer Institute Overview of the SEER Program [Internet]. 2010, Bethesda: National Cancer Institute, [Accessed 8/27/10], National Cancer Institute., http://healthservices.cancer.gov/seermedicare/program/remove.ruleout.dxcodes.macro.txt
27. National Cancer Institute Overview of the SEER Program [Internet]. 2010, Bethesda: National Cancer Institute, [Accessed 8/27/10], National Cancer Institute., http://healthservices.cancer.gov/seermedicare/program/charlson.comorbidity.macro.txt
28. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-83. 10.1016/0021-9681(87)90171-8, 3558716.
29. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-9. 10.1016/0895-4356(92)90133-8, 1607900.
30. Romano PS, Roos LL, Luft HS, Jollis JG, Doliszny K. A comparison of administrative versus clinical data: coronary artery bypass surgery as an example. Ischemic Heart Disease Patient Outcomes Research Team. J Clin Epidemiol 1994, 47:249-60. 10.1016/0895-4356(94)90006-X, 8138835.
31. Hu C, Xing Y, Cormier JN, Chang GJ. The validity of cause of death coding within the Surveillance, Epidemiology, and End Results (SEER) Registry. J Clin Oncol 2009, 27(15s):abstr 6544.